ArticleThe journal of prevention of Alzheimer's disease2025
Poor glymphatic function is associated with mild cognitive impairment and its progression to Alzheimer's disease: A DTI-ALPS study.
Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Glymphatic dysfunction in Alzheimer's disease: a systematic review and meta-analysis of the DTI-ALPS index as an imaging biomarker.Frontiers in aging neuroscience · 2026Pooled it
- Glymphatic Pathway Dysfunction in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis Using Diffusion Tensor Imaging Along the Perivascular Space.CNS neuroscience & therapeutics · 2025Pooled it
- Left-lateralized glymphatic dysfunction is associated with MoCA-measured cognitive impairment in cerebral small vessel disease: A DTI-ALPS study.IBRO neuroscience reports · 2026Article
- Physical exercise as a non-pharmacological strategy to enhance glymphatic function.IBRO neuroscience reports · 2026Review
- DTI-ALPS Is Associated with Temporolimbic Amyloid but Not Plasma p-Tau181 Across the Alzheimer's Disease Continuum.Research square · 2026Article
- Altered cerebrospinal fluid-based clearance mechanisms in aging autistic adults.Research square · 2026Article
- Association between MRI indicators of the glymphatic system and cognition in high-risk populations for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Glymphatic System Dysfunction in Central Nervous System Diseases.CNS neuroscience & therapeutics · 2026Review
- Mapping the Brain's Glymphatic System.Biomedicines · 2026Review
- Surrogates of glymphatic metrics decline and coupled sleep rhythms disruption in Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Application of diffusion tensor imaging analysis along perivascular spaces in evaluating glymphatic system function in type 2 diabetes mellitus.Frontiers in neuroscience · 2026Article
- Sleep and stress as modifiable drivers of Alzheimer's disease.NPJ dementia · 2026Review
- The Glymphatic System and Diaphragmatic Dysfunction in Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: The Importance of Inspiratory Rehabilitation Training.Journal of cardiovascular development and disease · 2025Review
- Perivascular spaces, diffusion MRI markers and cognitive decline in cerebral small vessel disease.Cerebral circulation - cognition and behavior · 2025Article
- Diffusion tensor imaging along the perivascular space and choroid plexus volume for assessing the brain glymphatic system in overt hypothyroidism.Frontiers in neurologyArticle
- Comprehensive and stratified meta-analysis of diffusion tensor image analysis along the perivascular space in Alzheimer's disease: Linking glymphatic dysfunction with cognitive decline and amyloid pathology.Journal of Alzheimer's disease reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to explore the association between ALPS index and both risks of MCI from cognitively normal (CN) and incident AD progressed from MCI, as well as potential mediating factors.
methodsThis study included 519 adults including 253 (48.75 %) CN and 266 (51.25 %) MCI participants from Alzheimer's Disease Neuroimaging Initiative. Glymphatic function (assessed by along the perivascular space [ALPS] index) was measured by diffusion tensor image at baseline. Neurobiomarkers (Aβ and tau from CSF, plasma and PET) and cognitive functions were served as mediators. Data were analyzed using Cox and Laplace regression and mediation analysis.
resultsDuring follow-up (median 3.6 years, interquartile range [IQR]: 2.0-4.9 years), 30 (11.86 %) participants developed MCI in the CN cohort and 73 (27.4 %) participants progressed to AD in the MCI cohort. The hazard ratios (95 % confidence intervals [CIs]) of the higher ALPS index was 0.605 (0.386-0.948) for MCI and 0.501 (0.356-0.706) for AD. In addition, participants with high ALPS index had 3.837 and 3.466 years prolonged onset of MCI and AD, separately. Aβ in choroid plexus (17.1 %), tau in cortex [Inferiortemporal (21.1 %), Middletemporal (AV1451:17.0 %, FTP:15.5 %), Superiortemporal(7.7 %), Meta_temporal (AV1451:17.5 %, FTP:16.6 %)], and executive function (14.1 %) mediated the association between ALPS and MCI-AD progression.
conclusionHigh ALPS index decreases MCI risk and delays MCI progression to AD by approximately 3.5 years. Aβ in choroid plexus, tau in cortex, and executive function may partially mediate the MCI-AD progression in relation to ALPS index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.